GLP-1 Agonist Formulation Low-Temperature Processing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
GLP-1 analogues are prone to chemical and physical instability, leading to fibril formation, which compromises their therapeutic efficacy, safety, and regulatory compliance due to potential immunogenicity and physical hazards.
Innovation Solution
A method for preparing GLP-1 agonist pharmaceutical compositions at low temperatures (2-15°C) with specific pH adjustment (6.5-8.5) and inclusion of tonicity modifiers, buffering agents, and preservatives, while maintaining low oxygen levels to minimize fibril formation and impurities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If heat treatment is applied to GLP-1 analogue solutions to increase shelf life, then stability is improved, but fibril formation increases leading to immunogenicity and safety risks
Solution Approach 1:
The patent changes the temperature parameter from conventional heat treatment (50-95°C) to low temperature processing (2-15°C). This parameter inversion resolves the contradiction by achieving stability improvement without triggering fibril formation, which occurs at higher temperatures. The low temperature approach maintains peptide stability while avoiding the harmful fibril aggregation that compromises safety and efficacy.
Solution Approach 2:
Instead of applying heat treatment to stabilize GLP-1 analogues, the patent inverts the conventional approach by using cold treatment. This inversion successfully addresses the technical contradiction by achieving the desired stability outcome through the opposite thermal condition, thereby preventing fibril formation while still extending shelf life.
2Stability of the object's composition
If heat treatment is applied to dissolve fibrils and delay formation, then fibril dissolution is improved, but therapeutic efficacy is lost due to denaturation
Solution Approach 1:
The patent changes the temperature parameter from heat treatment to low temperature processing (2-15°C). This parameter inversion resolves the contradiction by preventing fibril formation in the first place while maintaining the peptide's native structure and therapeutic efficacy. The low temperature approach achieves fibril management without the denaturation that occurs with heat treatment.
3Stability of the object's composition
If conventional heat treatment methods are used, then fibril formation is delayed, but manufacturing complexity and storage requirements increase
Solution Approach 1:
The patent changes the temperature parameter to low temperature processing (2-15°C) during manufacturing. This parameter modification resolves the contradiction by achieving fibril formation delay while simplifying storage requirements. The low temperature manufacturing approach creates a more stable formulation that requires less stringent storage conditions compared to heat-treated products.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method results in GLP-1 agonist compositions with reduced fibril formation and impurities, enhancing stability, safety, and cost-effectiveness for industrial-scale manufacturing.
Implementation Method 1
GLP-1 agonist compositions prepared according to the invention have a reduced number of fibrils and content of impurities, avoiding its formation in the manufacturing process
Implementation Method 2
adjusting the pH of the final solution between 6.5-8.5, preferably between 7.5-8.5, with a pH adjuster
Data Source
AI summary
The invention relates to a method for the preparation of a pharmaceutical composition comprising a GLP-1 agonist, a tonicity modifier, a buffering agent and a preservative which comprises the following steps: preparing a final solution comprising the tonicity modifier, the buffering agent, the preservative, the GLP-1 agonist and water for injection; and adjusting the pH of the final solution between 6.5-8.5 with a pH adjuster; wherein the final solution is prepared at a temperature between 2-15°C, preferably 2-10°C, more preferably 2-8 °C, most preferably 3-6°C.